Is HARROW, INC. (HROW) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 17.0% / 30% | 3.5% / 30% | 8.7% / 30% | 1.81% / 5% | ✓ HALAL |
| DJIM | 17.0% / 33% | 3.5% / 33% | 8.7% / 33% | 1.81% / 5% | ✓ HALAL |
| MSCI | 58.8% / 33% | 12.1% / 33% | 30.0% / 33% | 1.81% / 5% | ✗ NOT HALAL |
| S&P | 17.0% / 33% | 3.5% / 33% | 8.7% / 33% | 1.81% / 5% | ✓ HALAL |
| FTSE | 58.8% / 33% | 12.1% / 33% | 30.0% / 50% | 1.81% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 75.1% | |
| Operating Margin | 17.5% | |
| Net Margin | -1.9% | |
| Return on Equity (ROE) | -8.5% | |
| Return on Assets (ROA) | 4.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $44M |
| Free Cash Flow | $43M |
| Total Debt | $252M |
| Debt-to-Equity | 483.7 |
| Current Ratio | 2.2 |
| Total Assets | $399M |
Price & Trading
| Last Close | $35.38 |
| 50-Day MA | $43.25 |
| 200-Day MA | $40.57 |
| Avg Volume | 743K |
| Beta | 0.1 |
|
52-Week Range
$20.85
| |
About HARROW, INC. (HROW)
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Purification Calculator
As a halal stock with 1.81% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is HARROW, INC. (HROW) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), HARROW, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is HARROW, INC.'s debt ratio?
HARROW, INC.'s debt ratio is 17.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 58.8%.
Does HARROW, INC. require dividend purification?
Yes, HARROW, INC. has an impermissible income ratio of 1.81%, which means 1.81% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are HARROW, INC.'s key financial metrics?
HARROW, INC. has a market capitalization of $1.3B, and revenue of $272M. The company maintains a gross margin of 75.1% and a net margin of -1.9%. Return on equity stands at -8.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.